1073477-74-3 Usage
General Description
2-Fluoro-4-(trifluoromethoxy)phenol is a chemical compound that belongs to the chemical classes of phenols and fluorinated aryl compounds. It has the ability to accept two hydrogen bonds during bio-molecular interactions, making it a potentially active moiety in drugs. However, it's important to note that the safety, environmental impact, and potential uses of this compound require further research. Known for its reactivity and trifluoromethoxy group, this compound is a useful one in the development of bioactive molecules, but due to the presence of fluorine atoms, proper handling and disposal practices must be followed.
Check Digit Verification of cas no
The CAS Registry Mumber 1073477-74-3 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,7,3,4,7 and 7 respectively; the second part has 2 digits, 7 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 1073477-74:
(9*1)+(8*0)+(7*7)+(6*3)+(5*4)+(4*7)+(3*7)+(2*7)+(1*4)=163
163 % 10 = 3
So 1073477-74-3 is a valid CAS Registry Number.
1073477-74-3Relevant articles and documents
6-OXO-1,6-DIHYDROPYRIDAZINE DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF
-
, (2021/11/14)
A 6-oxo-1,6-dihydropyridazine derivative, a preparation method therefor and medical use thereof, in particular, a 6-oxo-1,6-dihydropyridazine derivative represented by general formula (I), a preparation method therefor, and a pharmaceutical composition containing the derivative, and use thereof as a NaV inhibitor and use thereof in the preparation of a drug for the treatment and/or prevention of pain and pain-related diseases. Each substituent in general formula (I) is the same as defined in the description.
PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF
-
, (2008/12/08)
The present invention relates to Pyrimidinone Derivatives, compositions comprising a Pyrimidinone Derivative, and methods of using the Pyrimidinone Derivatives for treating or preventing obesity, diabetes, a metabolic disorder, a cardiovascular disease or a disorder related to the activity of G protein-coupled receptor 119 ("GPR119") in a patient.
